MeSH tree: D02.540.505.760.500
Many cancer survivors live with the worry that their cancer might come back. This "recurrence" occurs when cancer cells hide somewhere in the body—like in the bone marrow—and start growing again, sometimes years later. Scientists ...
Oct 30, 2025
0
17
Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation ...
Oct 18, 2025
0
41
Researchers at the Central Institute of Mental Health (CIMH) in Mannheim, together with international partners, have developed patient-derived brain organoids for the first time in order to better understand the rare genetic ...
Oct 15, 2025
0
16
A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy everolimus to standard carboplatin chemotherapy extends the time before disease progression in patients ...
Aug 21, 2025
0
30
Researchers at Baylor College of Medicine and collaborating institutions have discovered a mechanism that drives the long-term decline in immune response that is observed after tuberculosis (TB) has been successfully treated. ...
Sep 30, 2024
0
44
Belzutifan, a hypoxia-inducible factor 2α (HIF-2α) inhibitor, improves progression-free survival and objective responses over everolimus among patients with advanced clear-cell renal cell carcinoma, according to a study published ...
Aug 23, 2024
0
43
When Lucas was diagnosed with a rare type of brain tumor at the age of six, there was no doubting the prognosis.
Feb 13, 2024
0
364
Women who inherit and carry a faulty BRCA2 gene have a substantially increased risk of developing breast cancer—approximately 70% of carriers will develop the disease over their lifetime.
Jan 16, 2024
0
46
Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic ...
Oct 22, 2023
0
70
A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus ...
Oct 21, 2023
0
144
